AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01601353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Genesis Cell Isolation System
Description: Liposuction followed by injection of autologous adipose derived cells
Study NCT00004931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00004931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01827696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ginseng
Description: Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
Study NCT01827696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
Study NCT02166762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLV interval measurement
Description: Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
Study NCT02203786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol.
Study NCT02278302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox®
Study NCT02278302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02278302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Study NCT02203786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine
Description: Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine.
Study NCT02203786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexedrine
Description: Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine.
Study NCT02278302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Study NCT02203786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.
Study NCT02203786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slot Machine
Description: 15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
Study NCT04494607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lowest Glycemic Index for a selected type fo cereal product
Description: determination of lowest Glycemic Index for a selected type fo cereal product
Study NCT02705573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Study NCT00756314 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Personalized contraceptive counseling
Description: The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
Study NCT00756314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized contraceptive counseling
Description: The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
Study NCT02882893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium Botulinum A Toxin
Study NCT02882893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum A Toxin
Study NCT03495895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minding the Baby
Description: Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
Study NCT03495895 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care condition
Study NCT04073303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
Study NCT00146107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 10 percent weight loss through diet and behavioral modification
Study NCT00146107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Multicomponent (resistance, aerobic, balance) exercise three times a week
Study NCT00146107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss and Exercise
Description: 10% weight loss through diet and exercise plus multicomponent exercise training three times a week
Study NCT03860883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Local Excision = 1cm Margin
Description: A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.
Study NCT03860883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision = 2cm Margin
Description: A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed.
Study NCT02873403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNEEMO knee brace
Description: Bespoke knee brace made by additive manufacturing
Study NCT02873403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Popular knee brace
Description: Customized knee brace used in the management of medial knee ostearthritis
Study NCT04637828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561
Description: study drug
Study NCT02272387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Study NCT02272387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01178827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride
Description: trospium chloride (60mg) once daily for 10 days
Study NCT01178827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin IR
Description: oxybutynin IR (5 mg) three times daily for 2 days
Study NCT01178827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxybutynin IR placebo
Description: oxybutynin IR placebo three times daily for 2 days
Study NCT03923985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic containing Lactobacillus Crispatus
Description: 1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
Study NCT03224637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine (conventional)
Study NCT04187001 — intervention group
Intervention type: OTHER
Intervention: Content Validity
Description: Use Delphi technique for achieve consensus
Study NCT04187001 — intervention group
Intervention type: OTHER
Intervention: Cultural adaptation
Description: Adapt the content to the target population
Study NCT04701255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification with intraocular lens implantation
Description: treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
Study NCT04701255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with intraocular lens implantation
Description: treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
Study NCT04701255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocular aberrometer assesment
Description: evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
Study NCT04701255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocular aberrometer assesment
Description: evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
Study NCT01038492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: p16 Methylation and Lung Cancer Education
Description: * patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits.
Study NCT04260724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: * stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )
Study NCT04260724 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham coil stimulation
Description: no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
Study NCT02227407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGOs(reciprocating gait orthoses)
Description: using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
Study NCT04559672 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical laminoplasty surgery
Description: The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
Study NCT04559672 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical laminectomy and fusion surgery
Description: The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
Study NCT01433081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion of .9 normal saline
Description: administration of .9 normal saline
Study NCT01433081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of magnesium sulfate
Description: administration of magnesium sulfate
Study NCT04431778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Study NCT04431778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks).
Study NCT02705573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Study NCT02164149 — intervention group
Intervention type: OTHER
Intervention: Patients with primary colon cancer
Description: CT scan two days after surgery
Study NCT01166464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text messaging for smoking cessation
Description: A 7-week program of daily text messages
Study NCT03323476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation (or not initiation) of Immunosuppressive Therapy
Description: Discontinuation (or not initiation) of Immunosuppressive Therapy
Study NCT03323476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Description: Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
Study NCT02002195 — intervention group
Intervention type: DRUG
Intervention: FOLFOX
Description: Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
Study NCT02002195 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
Study NCT01234714 — intervention group
Intervention type: OTHER
Intervention: Non-invasive Magnetic Resonance Imaging (MRI)
Description: Conventional pre-operative MRI
Study NCT01234714 — intervention group
Intervention type: PROCEDURE
Intervention: Major liver resection
Description: Hepatectomy of >= 3 liver segments
Study NCT03479684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene-directed dosage of warfarin
Description: the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
Study NCT03479684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard dosage of warfarin
Description: the first day given 4.5mg; adjusted dose based on INR from the second day
Study NCT04483219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI ± anti-PD-1 antibody
Description: After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.
Study NCT04297267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
Study NCT04297267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m2,d1，every 3 weeks
Study NCT04032262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Gastrointestinal and Parkinson's Disease
Description: Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
Study NCT01235416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 706
Description: In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
Study NCT02907957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLIR ONE
Description: Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
Study NCT02907957 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FLIR ONE
Description: Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
Study NCT02907957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia - Caudal Nerve Block
Description: Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
Study NCT01166464 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic text messages
Description: non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
Study NCT01137864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious disease specialist advice
Description: Indication, choice, dosing and duration of antimicrobial therapy
Study NCT03599726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg per day for week 1-2 or 5-6
Study NCT03599726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 mg per day for week 1-2 or 5-6
Study NCT02631031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: single oral dose of 160 mg valsartan under fasting conditions
Study NCT03015779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cultured autologous oral mucosal epithelial cell sheet
Description: a prospective study,Before and after self control
Study NCT02462837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Study NCT02462837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02666807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
Study NCT02666807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
Study NCT06082505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
Study NCT06082505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
Study NCT01939080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training with supervised sessions
Study NCT03136094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+12
Description: The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
Study NCT03136094 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SBIRT+Usual Care
Description: Patients receive usual SBIRT care
Study NCT02534155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip®
Description: one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
Study NCT02534155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve Surgery
Description: Repair or replace mitral valve